Blinding Procedures

Blinding Procedures describe the systematic methods employed in clinical trials to prevent participants, investigators, or outcome assessors from knowing treatment assignments, thereby reducing measurement bias and expectation effects that could distort efficacy and safety assessments in controlled studies evaluating investigational therapeutics.

The pharmaceutical industry implements rigorous blinding through multiple complementary measures. Double-blind designs conceal assignments from both participants and investigators. Central randomisation systems control allocation concealment. Matching placebo preparations are identical in appearance, taste, and smell to active treatments. Double-dummy designs maintain blinding when active comparators differ in dosage form. Independent outcome adjudication committees review endpoints without knowledge of treatment assignment. Unblinding logs document any necessary emergency unblinding. Biomarker-based assessments may inadvertently reveal treatment assignments requiring additional blinding considerations. As decentralised trials introduce remote assessments and wearable device measurements, blinding procedures continue adapting to maintain trial integrity across novel clinical research designs.